Abstract
Stroke is the most feared complication of atrial fibrillation but for over fifty years there has been no simple, effective preventative alternative to warfarin. The development of new risk algorithms such as CHADSVASC has resulted in more patients being recommended anticoagulation therapy. Fixed dose oral anticoagulation is a landmark in drug development for atrial fibrillation. The differences between the drugs are discussed and the trial data examined. As we enter this new frontier of therapy, there is no doubt that these drugs will transform the delivery of anticoagulation for patients with atrial fibrillation.
Keywords: Atrial fibrillation, apixaban, dabigatran, direct thrombin inhibitors, edoxaban, factor Xa, thromboembolism, warfarin, rivoroxaban.
Cardiovascular & Hematological Disorders-Drug Targets
Title:Atrial Fibrillation – New Frontiers in Anticoagulation
Volume: 14 Issue: 1
Author(s): Ranji Thomas, Pierre Le Page and Andrew R.J. Mitchell
Affiliation:
Keywords: Atrial fibrillation, apixaban, dabigatran, direct thrombin inhibitors, edoxaban, factor Xa, thromboembolism, warfarin, rivoroxaban.
Abstract: Stroke is the most feared complication of atrial fibrillation but for over fifty years there has been no simple, effective preventative alternative to warfarin. The development of new risk algorithms such as CHADSVASC has resulted in more patients being recommended anticoagulation therapy. Fixed dose oral anticoagulation is a landmark in drug development for atrial fibrillation. The differences between the drugs are discussed and the trial data examined. As we enter this new frontier of therapy, there is no doubt that these drugs will transform the delivery of anticoagulation for patients with atrial fibrillation.
Export Options
About this article
Cite this article as:
Thomas Ranji, Page Le Pierre and Mitchell R.J. Andrew, Atrial Fibrillation – New Frontiers in Anticoagulation, Cardiovascular & Hematological Disorders-Drug Targets 2014; 14 (1) . https://dx.doi.org/10.2174/1871529X1401140724094846
DOI https://dx.doi.org/10.2174/1871529X1401140724094846 |
Print ISSN 1871-529X |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-4063 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Novel, Unifying Phagomimetic Mechanism of Vancomycin Therapeutic Action and Toxicity: Polyphenol, Electron Transfer and Reactive Oxygen Species
Anti-Infective Agents in Medicinal Chemistry Editorial [ Hot Topic: Antidepressant Drug Design (Executive Editor: Lee E. Schechter)]
Current Pharmaceutical Design Editorial: Thematic Issue-Topic–Diabetic Cardiovascular Disease–An Unmet Medical Need: Emerging Targets and Therapies-Introduction to the Special Issue
Cardiovascular & Hematological Agents in Medicinal Chemistry HDL Elevators and Mimetics - Emerging Therapies for Atherosclerosis
Cardiovascular & Hematological Agents in Medicinal Chemistry Virtual Screening Strategies in Medicinal Chemistry: The State of the Art and Current Challenges
Current Topics in Medicinal Chemistry Patent Selections
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Cross Talk Among Leukocytes, Platelets, and Endothelial Cells and its Relevance to Atherosclerosis and Coronary Heart Disease
Current Nutrition & Food Science Pharmacoproteomics in Cardiac Hypertrophy and Atherosclerosis
Cardiovascular & Hematological Disorders-Drug Targets Interplay of Carotenoids with Cigarette Smoking: Implications in Lung Cancer
Current Medicinal Chemistry Peroxisome Proliferator-Activated Receptors and the Control of Fatty Acid Oxidation in Cardiac Hypertrophy
Mini-Reviews in Medicinal Chemistry Propionate: Hypophagic Effects Observed in Animal Models Might be Transposed to the Human Obesity Management
Current Nutrition & Food Science Resveratrol: New Avenues for a Natural Compound in Neuroprotection
Current Pharmaceutical Design The Deadly Quartet (Covid-19, Old Age, Lung Disease, and Heart Failure) Explains Why Coronavirus-Related Mortality in Northern Italy Was So High
Current Cardiology Reviews Postoperative Atrial Fibrillation - What Do We Really Know?
Current Vascular Pharmacology Rheumatoid Arthritis: An Evolutionary Force in Biologics
Current Pharmaceutical Design Uric Acid Metabolism in Pre-hypertension and the Metabolic Syndrome
Current Vascular Pharmacology “Seeing is Believing”: Perspectives of Applying Imaging Technology in Discovery Toxicology
Combinatorial Chemistry & High Throughput Screening COVID-19: An Update on Pathogenesis and Treatment
Current Pharmaceutical Design Dissecting Insulin Signaling Pathways: Individualised Therapeutic Targets for Diagnosis and Treatment of Insulin Resistant States
Endocrine, Metabolic & Immune Disorders - Drug Targets The Role of Natural Killer T Cells in Atherosclerosis
Current Immunology Reviews (Discontinued)